Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Netflix (NASDAQ: NFLX) stock rose 0.9% ahead of the release of the latest earnings report from the streaming giant after the ...

Scott Rubner, Citadel Securities' new head of equity and equity derivatives strategy, expects "robust" retail trading flows ...

He's a regular tracker of volatility control funds - "vol control" - or strategies used increasingly by big institutions such as pensions and longer-term endowment funds to keep risk on an even keel.

Find insight on Germany’s pharmaceutical industry, Novartis and more in the latest Market Talks covering Health Care.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...